Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Inv...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

SONIC® Drive-In Celebrates Teacher Appreciation Week with Bundle of Freebies for Educators • Choice Hotels International Unveils Year of Sustainability Milestones in Newly Published 2023 Environmental, Social, and Governa • National Philanthropic Trust Appoints Holly Welch Stubbing President and Chief Executive Officer • Gibson Dunn and Barrasso Usdin File Civil Rights Lawsuit to Secure Constitutional Rights of Young Woman Incarcerated for Over Si • Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women • LENSRXLAB Introduces Groundbreaking Vision Benefits Platform Catered to Diabetic Individuals • PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN • Brigadier General James A. Ryans II to Deliver Keynote Address at National University's 2024 Commencement on May 18 in Petco Par • Mercedes-Benz USA and Atlanta Falcons’ Bijan Robinson Team Up with Little Free Library to Build 175 Book-Sharing Boxes Acr • Prudential Financial empowers young changemakers with $15,000 each at Emerging Visionaries Summit • 2024 Report by Penny Finance Confirms: The Great Wealth Transfer Will Not Solve The Wealth Gap Crisis • Top Tutoring Firm and Education Nonprofit Team up to Offer Free Math Tutoring for Bay Area Students • Study from Phoenix Children's Research Institute Reveals New Way to Prevent Lung Cancer from Spreading • Shoreline Equity Partners Announces Investment in Prime Meats • Eiseman Jewels Celebrates Mother’s Day With Two Designer Trunk Shows • Dickens Sanomi Academy Celebrates 10 Years of Transforming Lives, Welcomes Michael Boulos and Tiffany Trump-Boulos • NTT DATA Introduces Sustainable Device-as-a-Service • Wrexham AFC Announces North American Summer Tour Dates • Marshalls Launches First-Ever "Good Stuff Style Collective" in Partnership with Celebrity Stylists Molly Dickson, Zerina Akers a • BioInnovation Institute & Science announce the launch of the Translational Medicine Prize for Innovations in Women´s H

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

BOSTON , February 02 /Businesswire/ - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, February 16, 2023 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March 2, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.